ClinicalTrials.gg
CompletedNCT02303574Updated Dec 11, 2018Results posted

Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study

A Phase 1 interventional study of AZD7986, oral solution, 1 to 50 mg/mL and Placebo, oral solution in Safety, Pharmacokinetics, Pharmacodynamics, Food Effect, sponsored by AstraZeneca. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-11.

Sponsored by AstraZeneca · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This is a phase I, randomised, single-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of AZD7986 in healthy volunteers

02

Conditions studied

  • Safety, Pharmacokinetics, Pharmacodynamics, Food Effect

Keywords

  • AZD7986, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect, First-in-human, Single Ascending Dose, Multiple Ascending Dose, Healthy Subjects
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated written prior to any study specific procedures.
  2. Healthy male or female subjects aged 18 to 50 years (inclusive) at screening with suitable veins for cannulation or repeated venepuncture.
  3. Females must be of non-, confirmed at screening by fulfilling one of the following criteria:

    • defined as amenorrhoea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle stimulating hormone (FSH) and luteinising hormone (LH) levels in the post menopausal range.
    • Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
  4. Male subjects must be non fertile, i.e., surgically sterilised with documentation of azoospermia or must practice an effective method to prevent pregnancies. Effective contraceptive methods are:

    • Sexual abstinence from before the first administration of the IMP until 3 months after final administration of the IMP, only if this is in line with the preferred and usual lifestyle of the subject.
    • Use of a condom plus spermicide agent in addition to having their partner use another acceptable method (oral or injectable hormonal contraceptives, contraceptive patch, intrauterine devices, vaginal hormonal rings, vaginal diaphragm or cervical caps) from before the first administration of the IMP until 3 months after final administration of the IMP.
    • Subject's sexual partner is of non childbearing potential, i.e., post menopausal or surgically sterilised (e.g., tubal ligation, hysterectomy in medical history).
  5. Have a (BMI) between 18.0 and 30.0 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive at screening.

Exclusion criteria

Exclusion Criteria:

  • History of any disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
  • History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
  • Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP.
  • Subject has increased risk of infection:

    • History and/or presence of tuberculosis (TB); positive result for interferon gamma release assay (IGRA) (i.e., QuantiFERON TB-Gold), subjects who have resided in regions where tuberculosis and mycosis are endemic during 90 days before screening, or who intend to visit such a region during the duration of the study i.e. deserts areas, Eastern Europe, Central and South America, Africa except Egypt, Russia, Asia, Indonesia
    • Oral body temperature of > 37.7°C on Day -1, or as judged by the Investigator.
    • Blood \< 1.7 x109/L (Screening and Day -1 morning sample).
    • Is in high risk-group for infection within the last 6 months (i.e., men who have had unprotected sex with men, women who have had sex without a condom with men who have sex with men, people who have had sex without a condom with a person who has lived or travelled in Africa, people who inject drugs, people who have had sex without a condom with somebody who has injected drugs, people who have caught another sexually transmitted infection, people who have received a blood transfusion while in Africa, eastern Europe, the countries of the former Soviet Union, Asia or central and southern America).
    • Other latent or chronic infections (e.g., recurrent sinusitis, genital or ocular herpes, urinary tract infection) or at risk of infection (surgery, trauma, or significant infection) within 90 days of screening, or history of skin abscesses within 90 days of screening.
    • Clinically significant lower respiratory tract infection not resolved within 4 weeks prior to screening, as determined by the Investigator.
    • Volunteers with active or neoplastic disease in the previous 5 years other than superficial basal cell carcinoma.
    • Disease history suggesting abnormal immune function.
    • Volunteers who have received live or in the 4 weeks prior to dosing.
    • High-sensitivity C-reactive protein above upper limit of laboratory reference range at screening and on Day -1.
  • Some subjects lacking functional dipeptidyl peptidase 1 (DPP1) enzyme have been described to have periodontitis and palmoplantar hyperkeratosis:

    • For Part 1a and Part 1b: Subjects with signs of current gingivitis/periodontitis. Gingival evaluation (by inspection) will be performed by a dental hygienist or trained study physician.
    • For Part 2: Subjects with a history of recurring gingivitis/periodontitis or signs of current gingivitis/periodontitis. Gingival evaluation will be performed by a dental hygienist or trained study physician. Evaluation of bleeding propensity due to gingivitis will be performed by using dental hygienist instrumentation. Exact measurement of gum pockets is not needed.
    • Subjects with a history of hyperkeratosis or erythema in palms or soles.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    AZD7986, single and mulltiple doses

    In Part 1 up to 8 cohorts with single doses starting with 5 mg AZD7986 as oral solution. In Part 2 up to 5 cohorts with multiple doses of AZD7986 as oral solution

    Drug: AZD7986, oral solution, 1 to 50 mg/mL

  • Placebo comparator
    Placebo, single and multiple doses

    In Part 1 up to 8 cohorts and in Part 2 up to 5 cohorts with matching placebo to AZD7986 as oral solution

    Drug: Placebo, oral solution

Interventions

  • DrugAZD7986, oral solution, 1 to 50 mg/mL

    Starting dose in single ascending dose part: 5 mg

  • DrugPlacebo, oral solution

    Matching placebo

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of AZD7986 by Assessment of the Number of Adverse Events (AEs) Following Administration of Oral Solution in Single Ascending Dose (SAD - Part 1a and 1b) and Multiple Ascending Doses (MAD -Part 2)

    To investigate the safety and tolerability of AZD7986 by assessment of AEs (non-serious and serious) following administration of oral solution in SAD (Part 1a - fasted state and 1b - fed state) and MAD (Part 2)

    Time frame: Part 1a and 1b: Day -1, Day 1 to Day 3 (spontaneous, at pre-dose, 3, 12, 24, 48 and 72 hours [h] post-dose), Day 4, Day 5 and follow-up (7-10 days after dosing [not for participants included in Part 1b]); Part 2: Day -1, Day 1 to Day 21/28 and follow-up

  2. Rate and Extent of Absorption AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Concentration (AUC(0-last)) for Part 1a and 1b - SAD

    To assess the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) for Part 1a (fasted state) and 1b (fed state) - SAD

    Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)

  3. Rate and Extent of Absorption of AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Analyte Concentration (AUC(0-last)) for Part 2 - MAD

    To assess the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28

  4. Rate and Extent of Absorption AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 1a and 1b - SAD

    To assess the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) for Part 1a (fasted state) and 1b (fed state) - SAD. AUC was estimated by AUC(0 last) + Clast/λz where Clast was the last observed quantifiable concentration.

    Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)

  5. Rate and Extent of Absorption of AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 2 - MAD

    To assess the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. Note: Day 1 data calculated over a 24 hour period and was therefore not comparable with the Day 21 and Day 28 data

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28

  6. Rate and Extent of Absorption of AZD7986 by Assessment of Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (AUCτ) for Part 2 - MAD

    To assess area under the plasma concentration-time curve from time zero to the end of the dosing interval (AUCτ) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. AUCτ: AUC from time zero to 24 hours post-dose presented on Day1

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28

  7. Rate and Extent of Absorption AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 1a and 1b - SAD

    To assess the observed maximum plasma concentration (Cmax) for Part 1a (fasted state) and 1b (fed state) - SAD. Cmax was taken directly from the individual concentration-time curve

    Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)

  8. Rate and Extent of Absorption of AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 2 - MAD

    To assessthe observed maximum plasma concentration (Cmax) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. Cmax was taken directly from the individual concentration-time curve

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28

  9. Rate and Extent of Absorption AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 1a and 1b - SAD

    To assess the time to reach maximum observed concentration (tmax) for Part 1a (fasted state) and 1b (fed state) - SAD; tmax was taken directly from the individual concentration-time curve

    Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)

  10. Rate and Extent of Absorption of AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 2 - MAD

    To assess the time to reach maximum observed concentration (tmax) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; tmax was taken directly from the individual concentration-time curve

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28

  11. Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 1a and 1b - SAD

    To assess the half life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½.λz) for Part 1a (fasted state) and 1b (fed state) - SAD

    Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)

  12. Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 2 - MAD

    To assess the apparent terminal elimination half-life (t½.λz) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; tmax was taken directly from the individual concentration-time curve. Note: Day 1 data were calculated over a 24 hour period and was therefore not comparable with the Day 21 and Day 28 data

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28

  13. Rate and Extent of Absorption AZD7986 by Assessment of the Mean Residence Time (MRT) for Part 1a and 1b - SAD

    To assess the mean residence time (MRT) for Part 1a (fasted state) and 1b (fed state) - SAD

    Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)

  14. Rate and Extent of Absorption of AZD7986 by Assessment of Mean Residence Time (MRT) for Part 2 - MAD

    To assess the mean residence time (MRT) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28

  15. Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 1a and 1b - SAD

    To assess the apparent clearance (CL/F) for Part 1a (fasted state) and 1b (fed state) - SAD; CL/F for parent drug was estimated as dose divided by AUC

    Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)

  16. Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 2 - MAD

    To assess the apparent clearance (CL/F) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; CL/F for parent drug was estimated as dose divided by AUC

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28

  17. Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 1a and 1b - SAD

    To assess the apparent volume of distribution (Vz/F) for Part 1a (fasted state) and 1b (fed state) - SAD; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz

    Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)

  18. Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 2 - MAD

    To assess the the apparent volume of distribution (Vz/F) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28

  19. Rate and Extent of Absorption of AZD7986 by Assessment of the Accumulation Ratio for (Rac(AUC(0-τ)) for Part 2 - MAD

    To assess the accumulation ratio for (Rac(AUC(0-τ)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as AUC(0-τ) Day 21/AUC(0-24) Day 1

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28

  20. Rate and Extent of Absorption of AZD7986 by Assessment of the Accumulation Ratio for Cmax (Rac(Cmax)) for Part 2 - MAD

    To assess the accumulation ratio for Cmax (Rac(Cmax)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as Cmax Day 21/Cmax Day 1

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28

  21. Rate and Extent of Absorption of AZD7986 by Assessment of the Temporal Change Parameter (TCP) for Part 2 - MAD

    To assess the temporal change parameter (TCP) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as AUC(0-τ) Day 21/AUC Day 1, if extrapolated part was less than 20%

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28

  22. Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Cumulative Amount of Analyte Excreted From 0 to 48 Hours (CumAe0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD

    To assess cumulative amount of analyte excreted from 0 to 48 hours (CumAe0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)

    Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)

  23. Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 48 Hours (Cumfe0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD

    To assess percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)

    Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)

  24. Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Renal Clearance From 0 to 48 Hours (CLR0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD

    To assess renal clearance from 0 to 48 hours (CLR0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)

    Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)

  25. Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Cumulative Amount of Analyte Excreted From 0 to 24 Hours (CumAe0-24)) Parameters for Part 2 - MAD

    To assess cumulative amount of analyte excreted from 0 to 24 hours (CumAe0-24) for Part 2

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28

  26. Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 24 Hours (Cumfe0-24)) Parameter for Part 2 - MAD

    To assess percentage of dose excreted unchanged into the urine from 0 to 24 hours (Cumfe0 24) for Part 2

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28

  27. Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Renal Clearance From 0 to 24 Hours (CLR0-24)) Parameter for Part 2 - MAD

    To assess renal clearance from 0 to 24 hours (CLR0-24) for Part 2

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28

  28. Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Cumulative Amount of Analyte Excreted From 0 to 48 Hours (CumAe0-48)) Parameter for Part 2 - MAD

    To assess Cumulative amount of analyte excreted from 0 to 48 hours (CumAe0-48)) for Part 2

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28

  29. Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 48 Hours (Cumfe0 48)) Parameter for Part 2 - MAD

    To assess Percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0 48) for Part 2

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28

  30. Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Renal Clearance From 0 to 48 Hours (CLR0-48)) Parameter for Part 2 - MAD

    To assess Percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0 48) for Part 2

    Time frame: Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28

Secondary outcomes

  1. Effect of Food on Absorption AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Concentration (AUC(0-last)) for Part 1a and 1b - SAD

    To assess the effect of food by evaluating the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) for Part 1a (fasted state) and 1b (fed state) - SAD

    Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)

  2. Effect of Food on Absorption AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 1a and 1b - SAD

    To assess the effect of food by evaluating the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) for Part 1a (fasted state) and 1b (fed state) - SAD. AUC was estimated by AUC(0 last) + Clast/λz where Clast was the last observed quantifiable concentration.

    Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)

  3. Effect of Food on Absorption AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 1a and 1b - SAD

    To assess the effect of food by evaluating the observed maximum plasma concentration (Cmax) for Part 1a (fasted state) and 1b (fed state) - SAD. Cmax was taken directly from the individual concentration-time curve

    Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)

  4. Effect of Food on Absorption AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 1a and 1b - SAD

    To assess the effect of food by evaluating the time to reach maximum observed concentration (tmax) for Part 1a (fasted state) and 1b (fed state) - SAD; tmax was taken directly from the individual concentration-time curve

    Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)

  5. Effect of Food on Absorption AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 1a and 1b - SAD

    To assess the effect of food by evaluating the half life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½.λz) for Part 1a (fasted state) and 1b (fed state) - SAD

    Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)

  6. Effect of Food on Absorption AZD7986 by Assessment of the Mean Residence Time (MRT) for Part 1a and 1b - SAD

    To assess the effect of food by evaluating the mean residence time (MRT) for Part 1a (fasted state) and 1b (fed state) - SAD

    Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)

  7. Effect of Food on Absorption AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 1a and 1b - SAD

    To assess the effect of food by evaluating the apparent clearance (CL/F) for Part 1a (fasted state) and 1b (fed state) - SAD; CL/F for parent drug was estimated as dose divided by AUC

    Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)

  8. Effect of Food on Absorption AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 1a and 1b - SAD

    To assess the effect of food by evaluating the apparent volume of distribution (Vz/F) for Part 1a (fasted state) and 1b (fed state) - SAD; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz

    Time frame: At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)

  9. Assessment of Mean Normalized Relative Neutrophil Elastase (NE) Activity in All Cohorts of Part 2

    Absolute neutrophil count (ANC) was evaluated as part of the safety laboratory assessments and to evaluate the pharmacodynamics (PD) marker

    Time frame: At Day 16, 21 ((last dosing day in Cohort 1), 25, 28 (last sampling day in Cohort 1 and last dosing day in Cohorts 2 and 3), 32, 38, 41 and 52

  10. Assessment of Absolute Neutrophil Count (ANC) in All Cohorts of Part 2

    Absolute neutrophil count (ANC) was evaluated as part of the safety laboratory assessments and to evaluate the pharmacodynamics (PD) marker

    Time frame: At Day 12 (pre-dose, 6 hours and 12 hours)

07

Results

Posted Dec 11, 2018

Participant flow

This study was conducted at PAREXEL Early Phase Clinical Unit London, Level 7, Northwick Park Hospital in London. Healthy male and female participants were enrolled.

Part 1a (Fasted State)- SAD
Participant flow — Part 1a (Fasted State)- SAD
MilestoneAZD7986 5 mg (Fasted State) - SADAZD7986 15 mg (Fasted State) - SADAZD7986 35 mg (Fasted State) - SADAZD7986 50 mg (Fasted State) - SADAZD7986 65 mg (Fasted State) - SADAZD7986 35 mg (Fed State) - SADAZD7986 10 mg - MADAZD7986 25 mg - MADAZD7986 40 mg - MADPlacebo
Started66666000015
Completed66566000015
Not completed0010000000
Withdrew: Withdrawal by subject0010000000
Part 1b (Fed State) - SAD
Participant flow — Part 1b (Fed State) - SAD
MilestoneAZD7986 5 mg (Fasted State) - SADAZD7986 15 mg (Fasted State) - SADAZD7986 35 mg (Fasted State) - SADAZD7986 50 mg (Fasted State) - SADAZD7986 65 mg (Fasted State) - SADAZD7986 35 mg (Fed State) - SADAZD7986 10 mg - MADAZD7986 25 mg - MADAZD7986 40 mg - MADPlacebo
Started0000050003
Completed0000050003
Not completed0000000000
Part 2 - Multiple Ascending Dose (MAD)
Participant flow — Part 2 - Multiple Ascending Dose (MAD)
MilestoneAZD7986 5 mg (Fasted State) - SADAZD7986 15 mg (Fasted State) - SADAZD7986 35 mg (Fasted State) - SADAZD7986 50 mg (Fasted State) - SADAZD7986 65 mg (Fasted State) - SADAZD7986 35 mg (Fed State) - SADAZD7986 10 mg - MADAZD7986 25 mg - MADAZD7986 40 mg - MADPlacebo
Started000000681012
Completed000000671012
Not completed0000000100
Withdrew: Adverse event0000000100

Outcome measures

PrimarySafety and Tolerability of AZD7986 by Assessment of the Number of Adverse Events (AEs) Following Administration of Oral Solution in Single Ascending Dose (SAD - Part 1a and 1b) and Multiple Ascending Doses (MAD -Part 2)

To investigate the safety and tolerability of AZD7986 by assessment of AEs (non-serious and serious) following administration of oral solution in SAD (Part 1a - fasted state and 1b - fed state) and MAD (Part 2)

Time frame:
Part 1a and 1b: Day -1, Day 1 to Day 3 (spontaneous, at pre-dose, 3, 12, 24, 48 and 72 hours [h] post-dose), Day 4, Day 5 and follow-up (7-10 days after dosing [not for participants included in Part 1b]); Part 2: Day -1, Day 1 to Day 21/28 and follow-up
Reported as:
Number · Participants
Safety and Tolerability of AZD7986 by Assessment of the Number of Adverse Events (AEs) Following Administration of Oral Solution in Single Ascending Dose (SAD - Part 1a and 1b) and Multiple Ascending Doses (MAD -Part 2)
ParticipantsPart 1a (Fasted State) - Single Ascending Dose (SAD)Part 1b (Fed State) - SADPart 2 - Multiple Ascending Dose (MAD)Placebo - Part 1a (Fasted State)- SADPlacebo - Part 1b (Fed State) - SADPlacebo - Part 2 - MAD
Any AE8223818
Any AE with outcome = death000000
Any serious adverse event (SAE) (including death)000000
Any AE leading to discontinuation of AZD7986001000
PrimaryRate and Extent of Absorption AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Concentration (AUC(0-last)) for Part 1a and 1b - SAD

To assess the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) for Part 1a (fasted state) and 1b (fed state) - SAD

Time frame:
At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Reported as:
Geometric mean · h·nmol/L
Rate and Extent of Absorption AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Concentration (AUC(0-last)) for Part 1a and 1b - SAD
h·nmol/LAZD7986 5mg - Part 1a (Fasted State) - SADAZD7986 15mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1a (Fasted State) - SADAZD7986 50mg - Part 1a (Fasted State) - SADAZD7986 65mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1b (Fed State) - SAD
Rate and Extent of Absorption AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Concentration (AUC(0-last)) for Part 1a and 1b - SAD839.0 ± 48.33855 ± 9.312430 ± 18.316470 ± 22.722880 ± 21.210790 ± 20.2
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Analyte Concentration (AUC(0-last)) for Part 2 - MAD

To assess the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Reported as:
Geometric mean · h·nmol/L
Rate and Extent of Absorption of AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Analyte Concentration (AUC(0-last)) for Part 2 - MAD
h·nmol/LAZD7986 10mg - Day 1 - Part 2 - MADAZD7986 25mg - Day 1 - Part 2 - MADAZD7986 40mg - Day 1 - Part 2 - MADAZD7986 10mg - Day 21 - Part 2 - MADAZD7986 25mg - Day 28 - Part 2 - MADAZD7986 40mg - Day 28 - Part 2 - MAD
Rate and Extent of Absorption of AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Analyte Concentration (AUC(0-last)) for Part 2 - MAD1278 ± 18.93256 ± 15.96427 ± 31.05135 ± 49.414320 ± 39.529550 ± 53.5
PrimaryRate and Extent of Absorption AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 1a and 1b - SAD

To assess the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) for Part 1a (fasted state) and 1b (fed state) - SAD. AUC was estimated by AUC(0 last) + Clast/λz where Clast was the last observed quantifiable concentration.

Time frame:
At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Reported as:
Geometric mean · h·nmol/L
Rate and Extent of Absorption AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 1a and 1b - SAD
h·nmol/LAZD7986 5mg - Part 1a (Fasted State) - SADAZD7986 15mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1a (Fasted State) - SADAZD7986 50mg - Part 1a (Fasted State) - SADAZD7986 65mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1b (Fed State) - SAD
Rate and Extent of Absorption AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 1a and 1b - SAD915.3 ± 46.14165 ± 10.813230 ± 19.617590 ± 25.224710 ± 21.511550 ± 22.6
Statistical analysis
  • AZD7986 5mg - Part 1a (Fasted State) - SAD vs AZD7986 15mg - Part 1a (Fasted State) - SAD vs AZD7986 35mg - Part 1a (Fasted State) - SAD vs AZD7986 50mg - Part 1a (Fasted State) - SAD vs AZD7986 65mg - Part 1a (Fasted State) - SAD · Slope: 1.287 · 95% CI 1.183 to 1.391
  • AZD7986 35mg - Part 1a (Fasted State) - SAD vs AZD7986 35mg - Part 1b (Fed State) - SAD · Ratio (%): 90.72 · 90% CI 83.72 to 98.31
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 2 - MAD

To assess the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. Note: Day 1 data calculated over a 24 hour period and was therefore not comparable with the Day 21 and Day 28 data

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Reported as:
Geometric mean · h·nmol/L
Rate and Extent of Absorption of AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 2 - MAD
h·nmol/LAZD7986 10mg - Day 1 - Part 2 - MADAZD7986 25mg - Day 1 - Part 2 - MADAZD7986 40mg - Day 1 - Part 2 - MADAZD7986 10mg - Day 21 - Part 2 - MADAZD7986 25mg - Day 28 - Part 2 - MADAZD7986 40mg - Day 28 - Part 2 - MAD
Rate and Extent of Absorption of AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 2 - MAD1778 ± 21.34957 ± 19.59866 ± 35.85565 ± 54.316660 ± 44.233220 ± 58.5
Statistical analysis
  • AZD7986 10mg - Day 1 - Part 2 - MAD vs AZD7986 10mg - Day 21 - Part 2 - MAD · Ratio (%): 159.40 · 90% CI 140.61 to 180.70
  • AZD7986 25mg - Day 1 - Part 2 - MAD vs AZD7986 25mg - Day 28 - Part 2 - MAD · Ratio (%): 151.82 · 90% CI 138.23 to 166.74
  • AZD7986 40mg - Day 1 - Part 2 - MAD vs AZD7986 40mg - Day 28 - Part 2 - MAD · Ratio (%): 158.68 · 90% CI 146.67 to 171.67
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (AUCτ) for Part 2 - MAD

To assess area under the plasma concentration-time curve from time zero to the end of the dosing interval (AUCτ) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. AUCτ: AUC from time zero to 24 hours post-dose presented on Day1

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Reported as:
Geometric mean · h·nmol/L
Rate and Extent of Absorption of AZD7986 by Assessment of Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (AUCτ) for Part 2 - MAD
h·nmol/LAZD7986 10mg - Day 1 - Part 2 - MADAZD7986 25mg - Day 1 - Part 2 - MADAZD7986 40mg - Day 1 - Part 2 - MADAZD7986 10mg - Day 21 - Part 2 - MADAZD7986 25mg - Day 28 - Part 2 - MADAZD7986 40mg - Day 28 - Part 2 - MAD
Rate and Extent of Absorption of AZD7986 by Assessment of Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (AUCτ) for Part 2 - MAD1277 ± 18.93259 ± 15.96433 ± 31.02834 ± 35.17499 ± 27.415660 ± 43.3
Statistical analysis
  • AZD7986 10mg - Day 1 - Part 2 - MAD vs AZD7986 25mg - Day 1 - Part 2 - MAD vs AZD7986 40mg - Day 1 - Part 2 - MAD vs AZD7986 10mg - Day 21 - Part 2 - MAD vs AZD7986 25mg - Day 28 - Part 2 - MAD vs AZD7986 40mg - Day 28 - Part 2 - MAD · Slope: 1.228 · 95% CI 0.9513 to 1.504
  • AZD7986 10mg - Day 1 - Part 2 - MAD vs AZD7986 10mg - Day 21 - Part 2 - MAD · Ratio (%): 159.40 · 90% CI 140.61 to 180.70
  • AZD7986 25mg - Day 1 - Part 2 - MAD vs AZD7986 25mg - Day 28 - Part 2 - MAD · Ratio (%): 151.82 · 90% CI 138.23 to 166.74
  • AZD7986 40mg - Day 1 - Part 2 - MAD vs AZD7986 40mg - Day 28 - Part 2 - MAD · Ratio (%): 158.68 · 90% CI 146.67 to 171.67
PrimaryRate and Extent of Absorption AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 1a and 1b - SAD

To assess the observed maximum plasma concentration (Cmax) for Part 1a (fasted state) and 1b (fed state) - SAD. Cmax was taken directly from the individual concentration-time curve

Time frame:
At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Reported as:
Geometric mean · nmol/L
Rate and Extent of Absorption AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 1a and 1b - SAD
nmol/LAZD7986 5mg - Part 1a (Fasted State) - SADAZD7986 15mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1a (Fasted State) - SADAZD7986 50mg - Part 1a (Fasted State) - SADAZD7986 65mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1b (Fed State) - SAD
Rate and Extent of Absorption AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 1a and 1b - SAD50.74 ± 47.2202.3 ± 16.0668.1 ± 26.71035 ± 11.51358 ± 24.2434.8 ± 14.0
Statistical analysis
  • AZD7986 5mg - Part 1a (Fasted State) - SAD vs AZD7986 15mg - Part 1a (Fasted State) - SAD vs AZD7986 35mg - Part 1a (Fasted State) - SAD vs AZD7986 50mg - Part 1a (Fasted State) - SAD vs AZD7986 65mg - Part 1a (Fasted State) - SAD · Slope: 1.302 · 95% CI 1.198 to 1.406
  • AZD7986 35mg - Part 1a (Fasted State) - SAD vs AZD7986 35mg - Part 1b (Fed State) - SAD · Ratio (%): 64.14 · 90% CI 55.07 to 74.70
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 2 - MAD

To assessthe observed maximum plasma concentration (Cmax) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2. Cmax was taken directly from the individual concentration-time curve

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Reported as:
Geometric mean · nmol/L
Rate and Extent of Absorption of AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 2 - MAD
nmol/LAZD7986 10mg - Day 1 - Part 2 - MADAZD7986 25mg - Day 1 - Part 2 - MADAZD7986 40mg - Day 1 - Part 2 - MADAZD7986 10mg - Day 21 - Part 2 - MADAZD7986 25mg - Day 28 - Part 2 - MADAZD7986 40mg - Day 28 - Part 2 - MAD
Rate and Extent of Absorption of AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 2 - MAD138.6 ± 18.3350.9 ± 19.3672.0 ± 37.0246.3 ± 26.2598.1 ± 15.51235 ± 37.7
Statistical analysis
  • AZD7986 10mg - Day 1 - Part 2 - MAD vs AZD7986 25mg - Day 1 - Part 2 - MAD vs AZD7986 40mg - Day 1 - Part 2 - MAD vs AZD7986 10mg - Day 21 - Part 2 - MAD vs AZD7986 25mg - Day 28 - Part 2 - MAD vs AZD7986 40mg - Day 28 - Part 2 - MAD · Slope: 1.157 · 95% CI 0.9285 to 1.385
PrimaryRate and Extent of Absorption AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 1a and 1b - SAD

To assess the time to reach maximum observed concentration (tmax) for Part 1a (fasted state) and 1b (fed state) - SAD; tmax was taken directly from the individual concentration-time curve

Time frame:
At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Reported as:
Median · Hour
Rate and Extent of Absorption AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 1a and 1b - SAD
HourAZD7986 5mg - Part 1a (Fasted State) - SADAZD7986 15mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1a (Fasted State) - SADAZD7986 50mg - Part 1a (Fasted State) - SADAZD7986 65mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1b (Fed State) - SAD
Rate and Extent of Absorption AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 1a and 1b - SAD0.50 ± 47.20.75 ± 16.00.75 ± 26.70.64 ± 11.50.75 ± 24.24.00 ± 14.0
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 2 - MAD

To assess the time to reach maximum observed concentration (tmax) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; tmax was taken directly from the individual concentration-time curve

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Reported as:
Median · Hour
Rate and Extent of Absorption of AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 2 - MAD
HourAZD7986 10mg - Day 1 - Part 2 - MADAZD7986 25mg - Day 1 - Part 2 - MADAZD7986 40mg - Day 1 - Part 2 - MADAZD7986 10mg - Day 21 - Part 2 - MADAZD7986 25mg - Day 28 - Part 2 - MADAZD7986 40mg - Day 28 - Part 2 - MAD
Rate and Extent of Absorption of AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 2 - MAD1.51 ± 21.30.75 ± 19.50.75 ± 35.81.50 (0.75 to 1.50)0.75 (0.52 to 2.00)1.12 (0.53 to 1.50)
PrimaryRate and Extent of Absorption AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 1a and 1b - SAD

To assess the half life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½.λz) for Part 1a (fasted state) and 1b (fed state) - SAD

Time frame:
At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Reported as:
Mean · Hour
Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 1a and 1b - SAD
HourAZD7986 5mg - Part 1a (Fasted State) - SADAZD7986 15mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1a (Fasted State) - SADAZD7986 50mg - Part 1a (Fasted State) - SADAZD7986 65mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1b (Fed State) - SAD
Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 1a and 1b - SAD19.96 ± 3.41625.92 ± 4.45223.80 ± 3.32824.52 ± 5.83625.50 ± 7.25424.24 ± 4.259
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 2 - MAD

To assess the apparent terminal elimination half-life (t½.λz) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; tmax was taken directly from the individual concentration-time curve. Note: Day 1 data were calculated over a 24 hour period and was therefore not comparable with the Day 21 and Day 28 data

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Reported as:
Mean · Hour
Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 2 - MAD
HourAZD7986 10mg - Day 1 - Part 2 - MADAZD7986 25mg - Day 1 - Part 2 - MADAZD7986 40mg - Day 1 - Part 2 - MADAZD7986 10mg - Day 21 - Part 2 - MADAZD7986 25mg - Day 28 - Part 2 - MADAZD7986 40mg - Day 28 - Part 2 - MAD
Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 2 - MAD12.82 ± 1.47714.85 ± 2.24415.85 ± 4.13225.85 ± 5.50133.78 ± 10.3130.04 ± 5.483
PrimaryRate and Extent of Absorption AZD7986 by Assessment of the Mean Residence Time (MRT) for Part 1a and 1b - SAD

To assess the mean residence time (MRT) for Part 1a (fasted state) and 1b (fed state) - SAD

Time frame:
At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Reported as:
Mean · Hour
Rate and Extent of Absorption AZD7986 by Assessment of the Mean Residence Time (MRT) for Part 1a and 1b - SAD
HourAZD7986 5mg - Part 1a (Fasted State) - SADAZD7986 15mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1a (Fasted State) - SADAZD7986 50mg - Part 1a (Fasted State) - SADAZD7986 65mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1b (Fed State) - SAD
Rate and Extent of Absorption AZD7986 by Assessment of the Mean Residence Time (MRT) for Part 1a and 1b - SAD27.03 ± 4.37334.94 ± 5.86332.15 ± 5.00332.19 ± 8.36033.76 ± 10.3533.73 ± 6.429
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of Mean Residence Time (MRT) for Part 2 - MAD

To assess the mean residence time (MRT) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Reported as:
Mean · Hour
Rate and Extent of Absorption of AZD7986 by Assessment of Mean Residence Time (MRT) for Part 2 - MAD
HourAZD7986 10mg - Day 1 - Part 2 - MADAZD7986 25mg - Day 1 - Part 2 - MADAZD7986 40mg - Day 1 - Part 2 - MADAZD7986 10mg - Day 21 - Part 2 - MADAZD7986 25mg - Day 28 - Part 2 - MADAZD7986 40mg - Day 28 - Part 2 - MAD
Rate and Extent of Absorption of AZD7986 by Assessment of Mean Residence Time (MRT) for Part 2 - MAD18.56 ± 2.24521.84 ± 3.06722.64 ± 5.84433.73 ± 9.66340.16 ± 10.5837.46 ± 8.157
PrimaryRate and Extent of Absorption AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 1a and 1b - SAD

To assess the apparent clearance (CL/F) for Part 1a (fasted state) and 1b (fed state) - SAD; CL/F for parent drug was estimated as dose divided by AUC

Time frame:
At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Reported as:
Mean · Litre/Hour
Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 1a and 1b - SAD
Litre/HourAZD7986 5mg - Part 1a (Fasted State) - SADAZD7986 15mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1a (Fasted State) - SADAZD7986 50mg - Part 1a (Fasted State) - SADAZD7986 65mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1b (Fed State) - SAD
Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 1a and 1b - SAD14.23 ± 7.5778.606 ± 0.93216.395 ± 1.2816.938 ± 1.7776.371 ± 1.3177.363 ± 1.810
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 2 - MAD

To assess the apparent clearance (CL/F) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; CL/F for parent drug was estimated as dose divided by AUC

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Reported as:
Mean · Litre/Hour
Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 2 - MAD
Litre/HourAZD7986 10mg - Day 1 - Part 2 - MADAZD7986 25mg - Day 1 - Part 2 - MADAZD7986 40mg - Day 1 - Part 2 - MADAZD7986 10mg - Day 21 - Part 2 - MADAZD7986 25mg - Day 28 - Part 2 - MADAZD7986 40mg - Day 28 - Part 2 - MAD
Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 2 - MAD13.61 ± 2.66512.20 ± 2.48510.24 ± 4.2068.786 ± 2.7728.165 ± 2.0256.577 ± 2.867
PrimaryRate and Extent of Absorption AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 1a and 1b - SAD

To assess the apparent volume of distribution (Vz/F) for Part 1a (fasted state) and 1b (fed state) - SAD; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz

Time frame:
At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Reported as:
Mean · Litre
Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 1a and 1b - SAD
LitreAZD7986 5mg - Part 1a (Fasted State) - SADAZD7986 15mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1a (Fasted State) - SADAZD7986 50mg - Part 1a (Fasted State) - SADAZD7986 65mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1b (Fed State) - SAD
Rate and Extent of Absorption AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 1a and 1b - SAD385.1 ± 129.6318.8 ± 46.72215.8 ± 29.62236.8 ± 39.64231.0 ± 67.56249.5 ± 24.96
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 2 - MAD

To assess the the apparent volume of distribution (Vz/F) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Reported as:
Mean · Litre
Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 2 - MAD
LitreAZD7986 10mg - Day 1 - Part 2 - MADAZD7986 25mg - Day 1 - Part 2 - MADAZD7986 40mg - Day 1 - Part 2 - MADAZD7986 10mg - Day 21 - Part 2 - MADAZD7986 25mg - Day 28 - Part 2 - MADAZD7986 40mg - Day 28 - Part 2 - MAD
Rate and Extent of Absorption of AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 2 - MAD248.9 ± 38.94256.7 ± 36.11222.7 ± 65.93311.8 ± 56.96393.2 ± 163.1269.6 ± 79.13
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of the Accumulation Ratio for (Rac(AUC(0-τ)) for Part 2 - MAD

To assess the accumulation ratio for (Rac(AUC(0-τ)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as AUC(0-τ) Day 21/AUC(0-24) Day 1

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Reported as:
Mean · Ratio
Rate and Extent of Absorption of AZD7986 by Assessment of the Accumulation Ratio for (Rac(AUC(0-τ)) for Part 2 - MAD
RatioAZD7986 10mg - Day 1 - Part 2 - MADAZD7986 25mg - Day 1 - Part 2 - MADAZD7986 40mg - Day 1 - Part 2 - MADAZD7986 10mg - Day 21 - Part 2 - MADAZD7986 25mg - Day 28 - Part 2 - MADAZD7986 40mg - Day 28 - Part 2 - MAD
Rate and Extent of Absorption of AZD7986 by Assessment of the Accumulation Ratio for (Rac(AUC(0-τ)) for Part 2 - MADNA ± NANA ± NANA ± NA2.257 ± 0.45602.330 ± 0.48282.476 ± 0.4521
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of the Accumulation Ratio for Cmax (Rac(Cmax)) for Part 2 - MAD

To assess the accumulation ratio for Cmax (Rac(Cmax)) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as Cmax Day 21/Cmax Day 1

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Reported as:
Mean · Ratio
Rate and Extent of Absorption of AZD7986 by Assessment of the Accumulation Ratio for Cmax (Rac(Cmax)) for Part 2 - MAD
RatioAZD7986 10mg - Day 1 - Part 2 - MADAZD7986 25mg - Day 1 - Part 2 - MADAZD7986 40mg - Day 1 - Part 2 - MADAZD7986 10mg - Day 21 - Part 2 - MADAZD7986 25mg - Day 28 - Part 2 - MADAZD7986 40mg - Day 28 - Part 2 - MAD
Rate and Extent of Absorption of AZD7986 by Assessment of the Accumulation Ratio for Cmax (Rac(Cmax)) for Part 2 - MADNA ± NANA ± NANA ± NA1.799 ± 0.30841.667 ± 0.20071.881 ± 0.4015
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of the Temporal Change Parameter (TCP) for Part 2 - MAD

To assess the temporal change parameter (TCP) following a single AZD7986 dose on Day 1 and daily dosing on Days 21 or 28 at 10, 25 and 40 mg in Part 2; estimated as AUC(0-τ) Day 21/AUC Day 1, if extrapolated part was less than 20%

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Reported as:
Mean · Ratio
Rate and Extent of Absorption of AZD7986 by Assessment of the Temporal Change Parameter (TCP) for Part 2 - MAD
RatioAZD7986 10mg - Day 1 - Part 2 - MADAZD7986 25mg - Day 1 - Part 2 - MADAZD7986 40mg - Day 1 - Part 2 - MADAZD7986 10mg - Day 21 - Part 2 - MADAZD7986 25mg - Day 28 - Part 2 - MADAZD7986 40mg - Day 28 - Part 2 - MAD
Rate and Extent of Absorption of AZD7986 by Assessment of the Temporal Change Parameter (TCP) for Part 2 - MADNA ± NANA ± NANA ± NA1.610 ± 0.25391.535 ± 0.24791.599 ± 0.2082
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Cumulative Amount of Analyte Excreted From 0 to 48 Hours (CumAe0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD

To assess cumulative amount of analyte excreted from 0 to 48 hours (CumAe0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)

Time frame:
At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Reported as:
Mean · nmol
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Cumulative Amount of Analyte Excreted From 0 to 48 Hours (CumAe0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD
nmolAZD7986 5mg - Part 1a (Fasted State) - SADAZD7986 15mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1a (Fasted State) - SADAZD7986 50mg - Part 1a (Fasted State) - SADAZD7986 65mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1b (Fed State) - SAD
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Cumulative Amount of Analyte Excreted From 0 to 48 Hours (CumAe0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD1318 ± 348.54820 ± 109616530 ± 214519660 ± 452127770 ± 1020018420 ± 2554
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 48 Hours (Cumfe0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD

To assess percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)

Time frame:
At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Reported as:
Mean · Percentage of dose excreted unchanged
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 48 Hours (Cumfe0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD
Percentage of dose excreted unchangedAZD7986 5mg - Part 1a (Fasted State) - SADAZD7986 15mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1a (Fasted State) - SADAZD7986 50mg - Part 1a (Fasted State) - SADAZD7986 65mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1b (Fed State) - SAD
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 48 Hours (Cumfe0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD11.09 ± 2.93113.51 ± 3.07419.86 ± 2.57816.53 ± 3.80217.97 ± 6.59822.13 ± 3.069
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Renal Clearance From 0 to 48 Hours (CLR0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD

To assess renal clearance from 0 to 48 hours (CLR0-48) after single dose administration of AZD7986 oral solution in Part 1a (fasted state) and 1b (fed state)

Time frame:
At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 h); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Reported as:
Mean · Liter/hour
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Renal Clearance From 0 to 48 Hours (CLR0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD
Liter/hourAZD7986 5mg - Part 1a (Fasted State) - SADAZD7986 15mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1a (Fasted State) - SADAZD7986 50mg - Part 1a (Fasted State) - SADAZD7986 65mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1b (Fed State) - SAD
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK Parameter (Renal Clearance From 0 to 48 Hours (CLR0-48)) Following Administration of Single Dose Oral Solution for Part 1a and 1b - SAD1.734 ± 0.3681.544 ± 0.28981.619 ± 0.21011.430 ± 0.15611.477 ± 0.51872.097 ± 0.1921
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Cumulative Amount of Analyte Excreted From 0 to 24 Hours (CumAe0-24)) Parameters for Part 2 - MAD

To assess cumulative amount of analyte excreted from 0 to 24 hours (CumAe0-24) for Part 2

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Reported as:
Mean · nmol
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Cumulative Amount of Analyte Excreted From 0 to 24 Hours (CumAe0-24)) Parameters for Part 2 - MAD
nmolAZD7986 10mg - Day 1 - Part 2 - MADAZD7986 25mg - Day 1 - Part 2 - MADAZD7986 40mg - Day 1 - Part 2 - MADAZD7986 10mg - Day 21 - Part 2 - MADAZD7986 25mg - Day 28 - Part 2 - MADAZD7986 40mg - Day 28 - Part 2 - MAD
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Cumulative Amount of Analyte Excreted From 0 to 24 Hours (CumAe0-24)) Parameters for Part 2 - MAD2295 ± 638.15540 ± 130511390 ± 24154002 ± 140211960 ± 466524970 ± 8075
SecondaryEffect of Food on Absorption AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Concentration (AUC(0-last)) for Part 1a and 1b - SAD

To assess the effect of food by evaluating the area under the plasma concentration versus time curve, from time zero to the time of the last quantifiable analyte concentration (AUC(0-last)) for Part 1a (fasted state) and 1b (fed state) - SAD

Time frame:
At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Reported as:
Geometric mean · h·nmol/L
Effect of Food on Absorption AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Concentration (AUC(0-last)) for Part 1a and 1b - SAD
h·nmol/LAZD7986 35mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1b (Fed State) - SAD
Effect of Food on Absorption AZD7986 by Assessment of the Area Under the Plasma Concentration Versus Time Curve, From Time Zero to the Time of the Last Quantifiable Concentration (AUC(0-last)) for Part 1a and 1b - SAD12430 ± 18.310790 ± 20.2
SecondaryEffect of Food on Absorption AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 1a and 1b - SAD

To assess the effect of food by evaluating the area under plasma concentration-time curve from zero extrapolated to infinity (AUC) for Part 1a (fasted state) and 1b (fed state) - SAD. AUC was estimated by AUC(0 last) + Clast/λz where Clast was the last observed quantifiable concentration.

Time frame:
At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Reported as:
Geometric mean · h·nmol/L
Effect of Food on Absorption AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 1a and 1b - SAD
h·nmol/LAZD7986 35mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1b (Fed State) - SAD
Effect of Food on Absorption AZD7986 by Assessment of the Area Under Plasma Concentration-time Curve From Zero Extrapolated to Infinity (AUC) for Part 1a and 1b - SAD13230 ± 19.611550 ± 22.6
SecondaryEffect of Food on Absorption AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 1a and 1b - SAD

To assess the effect of food by evaluating the observed maximum plasma concentration (Cmax) for Part 1a (fasted state) and 1b (fed state) - SAD. Cmax was taken directly from the individual concentration-time curve

Time frame:
At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Reported as:
Geometric mean · nmol/L
Effect of Food on Absorption AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 1a and 1b - SAD
nmol/LAZD7986 35mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1b (Fed State) - SAD
Effect of Food on Absorption AZD7986 by Assessment of the Observed Maximum Plasma Concentration (Cmax) for Part 1a and 1b - SAD668.1 ± 26.7434.8 ± 14.0
SecondaryEffect of Food on Absorption AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 1a and 1b - SAD

To assess the effect of food by evaluating the time to reach maximum observed concentration (tmax) for Part 1a (fasted state) and 1b (fed state) - SAD; tmax was taken directly from the individual concentration-time curve

Time frame:
At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Reported as:
Median · Hour
Effect of Food on Absorption AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 1a and 1b - SAD
HourAZD7986 35mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1b (Fed State) - SAD
Effect of Food on Absorption AZD7986 by Assessment of the Time to Reach Maximum Observed Concentration (Tmax) for Part 1a and 1b - SAD0.75 ± 26.74.00 ± 14.0
SecondaryEffect of Food on Absorption AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 1a and 1b - SAD

To assess the effect of food by evaluating the half life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½.λz) for Part 1a (fasted state) and 1b (fed state) - SAD

Time frame:
At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Reported as:
Mean · Hour
Effect of Food on Absorption AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 1a and 1b - SAD
HourAZD7986 35mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1b (Fed State) - SAD
Effect of Food on Absorption AZD7986 by Assessment of the Apparent Terminal Elimination Half-life (t½.λz) for Part 1a and 1b - SAD23.80 ± 3.32824.24 ± 4.259
SecondaryEffect of Food on Absorption AZD7986 by Assessment of the Mean Residence Time (MRT) for Part 1a and 1b - SAD

To assess the effect of food by evaluating the mean residence time (MRT) for Part 1a (fasted state) and 1b (fed state) - SAD

Time frame:
At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Reported as:
Mean · Hour
Effect of Food on Absorption AZD7986 by Assessment of the Mean Residence Time (MRT) for Part 1a and 1b - SAD
HourAZD7986 35mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1b (Fed State) - SAD
Effect of Food on Absorption AZD7986 by Assessment of the Mean Residence Time (MRT) for Part 1a and 1b - SAD32.15 ± 5.00333.73 ± 6.429
SecondaryEffect of Food on Absorption AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 1a and 1b - SAD

To assess the effect of food by evaluating the apparent clearance (CL/F) for Part 1a (fasted state) and 1b (fed state) - SAD; CL/F for parent drug was estimated as dose divided by AUC

Time frame:
At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Reported as:
Mean · Litre/Hour
Effect of Food on Absorption AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 1a and 1b - SAD
Litre/HourAZD7986 35mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1b (Fed State) - SAD
Effect of Food on Absorption AZD7986 by Assessment of the Apparent Clearance (CL/F) for Part 1a and 1b - SAD6.395 ± 1.2817.363 ± 1.810
SecondaryEffect of Food on Absorption AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 1a and 1b - SAD

To assess the effect of food by evaluating the apparent volume of distribution (Vz/F) for Part 1a (fasted state) and 1b (fed state) - SAD; Vz/F at terminal phase (extravascular administration) was estimated by dividing the apparent clearance (CL/F) by λz

Time frame:
At Day 1 (Pre-dose, 0.5, 1, 2, 3, 4, 5, 7, 8, 9, 12 hours); Day 2 (24 h); Day 3 (48 h); Day 4 (72 h) and Day 5 (96 h)
Reported as:
Mean · Litre
Effect of Food on Absorption AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 1a and 1b - SAD
LitreAZD7986 35mg - Part 1a (Fasted State) - SADAZD7986 35mg - Part 1b (Fed State) - SAD
Effect of Food on Absorption AZD7986 by Assessment of the Apparent Volume of Distribution (Vz/F) for Part 1a and 1b - SAD215.8 ± 29.62249.5 ± 24.96
SecondaryAssessment of Mean Normalized Relative Neutrophil Elastase (NE) Activity in All Cohorts of Part 2

Absolute neutrophil count (ANC) was evaluated as part of the safety laboratory assessments and to evaluate the pharmacodynamics (PD) marker

Time frame:
At Day 16, 21 ((last dosing day in Cohort 1), 25, 28 (last sampling day in Cohort 1 and last dosing day in Cohorts 2 and 3), 32, 38, 41 and 52
Reported as:
Mean · Percentage change in NE activity
Assessment of Mean Normalized Relative Neutrophil Elastase (NE) Activity in All Cohorts of Part 2
Percentage change in NE activityAZD7986 10mg - Part 2 - MADAZD7986 25mg - Part 2 - MADAZD7986 40mg - Part 2 - MADPlacebo - Part 2 - MAD
Day 16-7.53 ± 11.59-28.25 ± 22.33-28.10 ± 16.877.39 ± 13.06
Day 21-26.13 ± 3.116-36.73 ± 11.76-52.31 ± 14.901.39 ± 20.14
Day 25-30.15 ± 8.412-40.06 ± 6.609-59.02 ± 11.77-5.15 ± 14.14
Day 28-39.22 ± 9.141-45.05 ± 8.304-55.24 ± 9.087-16.36 ± 22.03
Day 32NA ± NA-53.35 ± 8.292-46.29 ± 37.55-6.216 ± 14.28
Day 38NA ± NA-54.42 ± 6.800-65.44 ± 7.556-19.51 ± 10.74
Day 41NA ± NA-53.46 ± 9.774-62.56 ± 8.324-18.14 ± 15.62
Day 52NA ± NA-17.73 ± 18.07-21.31 ± 18.07-20.98 ± 15.32
SecondaryAssessment of Absolute Neutrophil Count (ANC) in All Cohorts of Part 2

Absolute neutrophil count (ANC) was evaluated as part of the safety laboratory assessments and to evaluate the pharmacodynamics (PD) marker

Time frame:
At Day 12 (pre-dose, 6 hours and 12 hours)
Reported as:
Mean · 10^9 neutrophils/L
Assessment of Absolute Neutrophil Count (ANC) in All Cohorts of Part 2
10^9 neutrophils/LAZD7986 10mg - Part 2 - MADAZD7986 25mg - Part 2 - MADAZD7986 40mg - Part 2 - MADPlacebo - Part 2 - MAD
Day 12, Pre-dose2.757 ± 0.41782.881 ± 0.52222.560 ± 0.91082.945 ± 0.7966
Day 12, 6 hNA ± NA3.401 ± 1.0493.129 ± 0.72103.402 ± 1.178
Day 12, 12 hNA ± NA3.454 ± 0.74483.460 ± 0.52483.247 ± 0.7622
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 24 Hours (Cumfe0-24)) Parameter for Part 2 - MAD

To assess percentage of dose excreted unchanged into the urine from 0 to 24 hours (Cumfe0 24) for Part 2

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Reported as:
Mean · Percentage of dose excreted unchanged
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 24 Hours (Cumfe0-24)) Parameter for Part 2 - MAD
Percentage of dose excreted unchangedAZD7986 10mg - Day 1 - Part 2 - MADAZD7986 25mg - Day 1 - Part 2 - MADAZD7986 40mg - Day 1 - Part 2 - MADAZD7986 10mg - Day 21 - Part 2 - MADAZD7986 25mg - Day 28 - Part 2 - MADAZD7986 40mg - Day 28 - Part 2 - MAD
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 24 Hours (Cumfe0-24)) Parameter for Part 2 - MAD9.650 ± 2.6839.319 ± 2.19511.98 ± 2.53916.83 ± 5.89420.12 ± 7.84726.25 ± 8.489
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Renal Clearance From 0 to 24 Hours (CLR0-24)) Parameter for Part 2 - MAD

To assess renal clearance from 0 to 24 hours (CLR0-24) for Part 2

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Reported as:
Mean · Liter/hour
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Renal Clearance From 0 to 24 Hours (CLR0-24)) Parameter for Part 2 - MAD
Liter/hourAZD7986 10mg - Day 1 - Part 2 - MADAZD7986 25mg - Day 1 - Part 2 - MADAZD7986 40mg - Day 1 - Part 2 - MADAZD7986 10mg - Day 21 - Part 2 - MADAZD7986 25mg - Day 28 - Part 2 - MADAZD7986 40mg - Day 28 - Part 2 - MAD
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Renal Clearance From 0 to 24 Hours (CLR0-24)) Parameter for Part 2 - MAD1.784 ± 0.46061.685 ± 0.34411.782 ± 0.3841NA ± NANA ± NANA ± NA
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Cumulative Amount of Analyte Excreted From 0 to 48 Hours (CumAe0-48)) Parameter for Part 2 - MAD

To assess Cumulative amount of analyte excreted from 0 to 48 hours (CumAe0-48)) for Part 2

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Reported as:
Mean · nmol
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Cumulative Amount of Analyte Excreted From 0 to 48 Hours (CumAe0-48)) Parameter for Part 2 - MAD
nmolAZD7986 10mg - Day 1 - Part 2 - MADAZD7986 25mg - Day 1 - Part 2 - MADAZD7986 40mg - Day 1 - Part 2 - MADAZD7986 10mg - Day 21 - Part 2 - MADAZD7986 25mg - Day 28 - Part 2 - MADAZD7986 40mg - Day 28 - Part 2 - MAD
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Cumulative Amount of Analyte Excreted From 0 to 48 Hours (CumAe0-48)) Parameter for Part 2 - MADNA ± NANA ± NANA ± NA6525 ± 268418680 ± 876536160 ± 12030
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 48 Hours (Cumfe0 48)) Parameter for Part 2 - MAD

To assess Percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0 48) for Part 2

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Reported as:
Mean · Percentage of dose excreted unchanged
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 48 Hours (Cumfe0 48)) Parameter for Part 2 - MAD
Percentage of dose excreted unchangedAZD7986 10mg - Day 1 - Part 2 - MADAZD7986 25mg - Day 1 - Part 2 - MADAZD7986 40mg - Day 1 - Part 2 - MADAZD7986 10mg - Day 21 - Part 2 - MADAZD7986 25mg - Day 28 - Part 2 - MADAZD7986 40mg - Day 28 - Part 2 - MAD
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Percentage of Dose Excreted Unchanged Into the Urine From 0 to 48 Hours (Cumfe0 48)) Parameter for Part 2 - MADNA ± NANA ± NANA ± NA27.44 ± 11.2931.42 ± 14.7438.01 ± 12.65
PrimaryRate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Renal Clearance From 0 to 48 Hours (CLR0-48)) Parameter for Part 2 - MAD

To assess Percentage of dose excreted unchanged into the urine from 0 to 48 hours (Cumfe0 48) for Part 2

Time frame:
Day 1 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24 h); Day 21 (pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 8, 9, 12, 24, 72, 96 h) and Day 28
Reported as:
Mean · Liter/hour
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Renal Clearance From 0 to 48 Hours (CLR0-48)) Parameter for Part 2 - MAD
Liter/hourAZD7986 10mg - Day 1 - Part 2 - MADAZD7986 25mg - Day 1 - Part 2 - MADAZD7986 40mg - Day 1 - Part 2 - MADAZD7986 10mg - Day 21 - Part 2 - MADAZD7986 25mg - Day 28 - Part 2 - MADAZD7986 40mg - Day 28 - Part 2 - MAD
Rate and Extent of Absorption of AZD7986 by Assessment of Urine PK (Renal Clearance From 0 to 48 Hours (CLR0-48)) Parameter for Part 2 - MADNA ± NANA ± NANA ± NA1.508 ± 0.4381.618 ± 0.50851.527 ± 0.3418

Adverse events

Collected over Part 1a and 1b: Day -1, Day 1 to Day 3 (spontaneous, at pre-dose, 3, 12, 24, 48 and 72 hours [h] post-dose), Day 4, Day 5 and follow-up (7-10 days after dosing [not for participants included in Part 1b]); Part 2: Day -1, Day 1 to Day 21/28 and follow-up. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1a (Fasted State) - Single Ascending Dose (SAD)0/30 (0%)0/30 (0%)8/30 (26.7%)
Part 1b (Fed State) - SAD0/5 (0%)0/5 (0%)2/5 (40%)
Part 2 - Multiple Ascending Dose (MAD)0/24 (0%)0/24 (0%)23/24 (95.8%)
Placebo - Part 1a (Fasted State)- SAD0/15 (0%)0/15 (0%)8/15 (53.3%)
Placebo - Part 1b (Fed State) - SAD0/3 (0%)0/3 (0%)1/3 (33.3%)
Placebo - Part 2 - MAD0/12 (0%)0/12 (0%)8/12 (66.7%)
Most frequent other events
Showing 10 of 56
Most frequent other events
EventPart 1a (Fasted State) - Single Ascending Dose (SAD)Part 1b (Fed State) - SADPart 2 - Multiple Ascending Dose (MAD)Placebo - Part 1a (Fasted State)- SADPlacebo - Part 1b (Fed State) - SADPlacebo - Part 2 - MAD
HeadacheNervous system disorders3/302/56/242/150/31/12
Gingival bleedingGastrointestinal disorders0/301/53/241/151/32/12
EpistaxisRespiratory, thoracic and mediastinal disorders0/301/50/240/150/30/12
Nasal congestionRespiratory, thoracic and mediastinal disorders0/301/50/240/150/32/12
Dermatitis contactSkin and subcutaneous tissue disorders0/301/52/240/150/30/12
ConstipationGastrointestinal disorders0/300/54/240/150/32/12
DizzinessNervous system disorders1/300/52/241/150/32/12
Feeling hotGeneral disorders0/300/50/240/150/32/12
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/300/53/241/150/32/12
NasopharyngitisInfections and infestations1/300/53/240/150/31/12

Baseline characteristics

Age, Continuous
Age, Continuous(Years)AZD7986 5 mg (Fasted State) - SADAZD7986 15 mg (Fasted State) - SADAZD7986 35 mg (Fasted State) - SADAZD7986 50 mg (Fasted State) - SADAZD7986 65 mg (Fasted State) - SADAZD7986 35 mg (Fed State) - SADAZD7986 10 mg - MADAZD7986 25 mg - MADAZD7986 40 mg - MADPlacebo - Part 1a (Fasted)Placebo - Part 1b (Fed State)Placebo - Part 2Total
Part 1a28.5 ± 5.3929.7 ± 8.7826.2 ± 3.6632.2 ± 10.529.7 ± 6.65———————29.2 ± 7.14
Part 1b—————26.6 ± 3.91——————26.6 ± 3.91
Part 2——————30.7 ± 5.6538.4 ± 7.2534.4 ± 9.17———34.8 ± 8.05
Part 1a Placebo—————————29.9 ± 7.24——29.9 ± 7.24
Part 1b Placebo——————————28.7 ± 8.5—28.7 ± 8.5
Part 2 Placebo———————————36.2 ± 7.236.2 ± 7.2
Sex: Female, Male
Sex: Female, Male(Participants)AZD7986 5 mg (Fasted State) - SADAZD7986 15 mg (Fasted State) - SADAZD7986 35 mg (Fasted State) - SADAZD7986 50 mg (Fasted State) - SADAZD7986 65 mg (Fasted State) - SADAZD7986 35 mg (Fed State) - SADAZD7986 10 mg - MADAZD7986 25 mg - MADAZD7986 40 mg - MADPlacebo - Part 1a (Fasted)Placebo - Part 1b (Fed State)Placebo - Part 2Total
Part 1a — Female0000000000000
Part 1a — Male666660000150045
Part 1b — Female0000000000000
Part 1b — Male0000050000308
Part 2 — Female0000000000000
Part 2 — Male0000006810001236
08

Study locations

1 site
  • Research Site
    Harrow, HA1 3UJ, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2014 to primary completion in Aug 2016, 20 months.

Results were first posted in Dec 2018, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2014
First posted
Dec 1, 2014
StartActual
Dec 3, 2014
Primary completionActual
Aug 3, 2016
CompletionActual
Aug 3, 2016
Results first posted
Dec 11, 2018
Last update
Dec 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02303574
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 1, 2014
Start date
Dec 3, 2014
Primary completion
Aug 3, 2016
Completion
Aug 3, 2016
Results posted
Dec 11, 2018
Last update
Dec 11, 2018

Study contacts

Annelize Koch, Dr
principal investigator · PAREXEL Early Phase Clinical Unit, Level 7, Northwick Park Hospital, Watford Road, Harrow, Middlesex, HA1 3UJ, United Kingdom
Bengt Larsson
study chair · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion